#ECTRIMS2019 - Early Ocrevus Use in PPMS Slows Disability, Including Risk of Wheelchair Reliance
Primary-Progressive MS: 6 Top Technology Recommendations
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology
Blood Neurofilament Light in Progressive Multiple Sclerosis | Neurology
Time to, and age at, EDSS 4.0, 6.0 and 8.0 based upon Kaplan-Meier... | Download Table
My Taking My Life Back Bucket List | MS And Me Media
PPMS: Prognosis and Life Expectancy | MyMSTeam
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials - eBioMedicine
10 Essential Facts About Primary-Progressive MS
Part I: Understanding Progression in MS | MSAA
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021 | Neurology and Therapy
Navigating Life with PPMS | MultipleSclerosis.net
Ocrevus May Delay by 7 Years PPMS Patients' Need for Wheelchair
Why I Feel Overlooked Living With a Rare Type of MS (PPMS)
MS Progression Chart: Stages of MS, Disability Scale, and More
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library
DMTs may reduce risk for becoming wheelchair dependent in patients with PPMS
PDF] Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. | Semantic Scholar
When Is the Best Time to Use an Automatic Wheelchair?
The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library